Eli Lilly and Company $LLY Stock Holdings Cut by TIAA Trust National Association

TIAA Trust National Association cut its position in shares of Eli Lilly and Company (NYSE:LLY) by 9.1% during the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 82,301 shares of the company’s stock after selling 8,275 shares during the quarter. TIAA Trust National Association’s holdings in Eli Lilly and Company were worth $64,155,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of the company. Wealth Preservation Advisors LLC acquired a new stake in Eli Lilly and Company in the 1st quarter valued at about $27,000. Blume Capital Management Inc. raised its holdings in shares of Eli Lilly and Company by 46.7% in the 2nd quarter. Blume Capital Management Inc. now owns 44 shares of the company’s stock worth $34,000 after purchasing an additional 14 shares in the last quarter. IMG Wealth Management Inc. acquired a new stake in Eli Lilly and Company during the second quarter valued at approximately $35,000. Financial Gravity Asset Management Inc. acquired a new stake in Eli Lilly and Company during the first quarter valued at approximately $40,000. Finally, TD Capital Management LLC boosted its holdings in Eli Lilly and Company by 129.2% during the first quarter. TD Capital Management LLC now owns 55 shares of the company’s stock worth $46,000 after buying an additional 31 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Up 2.2%

Shares of Eli Lilly and Company stock opened at $862.96 on Friday. The stock has a 50-day moving average price of $780.74 and a 200 day moving average price of $771.71. The company has a market cap of $816.76 billion, a P/E ratio of 56.40, a P/E/G ratio of 1.21 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $935.63.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share for the quarter, beating the consensus estimate of $6.42 by $0.60. The company had revenue of $17.60 billion for the quarter, compared to analysts’ expectations of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business’s revenue for the quarter was up 53.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Shareholders of record on Friday, November 14th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is currently 39.22%.

Insider Transactions at Eli Lilly and Company

In other news, Director Gabrielle Sulzberger bought 117 shares of the company’s stock in a transaction on Tuesday, August 12th. The shares were bought at an average cost of $641.18 per share, with a total value of $75,018.06. Following the transaction, the director directly owned 2,703 shares in the company, valued at approximately $1,733,109.54. This trade represents a 4.52% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jamere Jackson acquired 200 shares of the business’s stock in a transaction that occurred on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the transaction, the director owned 9,402 shares of the company’s stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have acquired 4,514 shares of company stock worth $2,894,841. 0.13% of the stock is owned by company insiders.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. HSBC increased their price objective on Eli Lilly and Company from $700.00 to $800.00 in a research report on Wednesday, October 1st. Erste Group Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a research report on Tuesday, October 14th. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. Wall Street Zen raised Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Finally, Leerink Partners reiterated a “market perform” rating and issued a $715.00 target price on shares of Eli Lilly and Company in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $940.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.